ALS Ltd delivers $3 billion revenue in FY25, unveils $350 million equity raise

ALS Ltd reported FY25 underlying revenue up 16% to $3 billion and EBIT of $515 million, a 4.7% increase year-over-year, while announcing a $350 million equity raise at $16.70 per share to fund expansion in its minerals and environmental testing labs and pursue further acquisitions. Despite a slight decline in underlying NPAT, statutory NPAT surged due to the prior year’s one-off impairment, and the company declared a total dividend of 38.6 cents per share, maintaining a 60% payout ratio, with management highlighting the strength of its diversified business model and the successful integration of recent acquisitions.

Analysis

ALS Ltd has reported strong financial results for FY25, demonstrating growth and resilience. Underlying revenue increased by 16% to $3 billion, and underlying EBIT rose 4.7% year-on-year to $515 million (or 7.7% to $529.8 million on a constant currency basis). Although underlying NPAT saw a slight decline of 1.4% to $312.1 million, it grew 2.8% in constant currency terms, while statutory NPAT experienced a significant surge of 1,886% to $256.2 million, primarily due to a prior-year one-off impairment related to Nuvisan. The company maintained robust free cash flow conversion at 95%, generating $591 million. Operationally, the commodities division showed resilience with its minerals business maintaining margins above 31% and mine site expansion revenue growing 24%. The life sciences division also performed well, with environmental testing leading organic revenue growth at 9.8%. Concurrent with these results, ALS announced a $350 million fully underwritten institutional placement at $16.70 per share, a 5.3% discount to the last traded price, alongside a potential $40 million share purchase plan. These funds are earmarked for expanding laboratory capacity in its minerals and environmental divisions ($230 million), pursuing M&A opportunities, and enhancing balance sheet flexibility. Management anticipates these organic investments will be mid-single digit EPS accretive on a pro forma FY25 basis once operational. Post-raise, ALS will possess $677 million in undrawn bank capacity and a pro forma leverage ratio of 1.7x, indicating a strengthened position for future growth initiatives. The company declared a total dividend of 38.6 cents per share, maintaining its 60% payout ratio.

Key Decisions for Investors

• Investors should evaluate the strategic rationale behind the $350 million equity raise, recognizing that while it introduces approximately 4.3% dilution, the proceeds are allocated to high-growth areas and capacity expansions expected to be EPS accretive.
• The placement price of $16.70 per share, offered at a 5.3% discount, presents a potential entry point, but this should be weighed against the company's execution risk on new investments and the integration of future acquisitions.
• Monitor the company's progress in deploying capital from the equity raise, particularly the timeline and efficiency of lab upgrades and the successful integration of any new acquisitions in minerals and environmental segments.
• Consider the company's sustained 60% dividend payout ratio and strong free cash flow conversion as indicators of financial health, while noting the pro forma leverage of 1.7x post-raise provides significant capacity for further strategic growth.